Guselkumab (Janssen)

You are here

Tremfya® (guselkumab) (Janssen)

Guselkumab (CNTO1959) is a HuCAL-antibody specific to IL23p19 and is developed by Janssen Biotech/Johnson & Johnson. The program has concluded phase 2 clinical trials for the indications psoriasis, rheumatoid arthritis and palmoplantar pustulosis. In spring 2014, promising data from the phase 2b-trial in psoriasis have been published. The antibody is currently being evaluated in six phase 3-trials.

Guselkumab is a very good example of the power of HuCAL, the antibody having been engineered to be specific for IL23. The absolute specificity of guselkumab for IL23 is expected to translate into both efficacy and safety advantages.

More information about Tremfya® Study Information on